FDA Approval for Provention Bio (PRVB).
Re-cork the Champagne!
We were contemplating (dreaming) about an opening price over $12, and then a drift up...
Adding Ardelyx (ARDX) $1.57 to Watch List.
FDA Advisory Committee Says Go Forth Young Man!
While we hadn't previously owned Ardelyx, nor are they a...
Provention Biosciences (PRVB) Enters the Danger Zone.
Chart Looks Beautiful - But Nervous is why, we use soft and dry.
LIVE QUOTE
We'll...
Progressive Care (RXMD) Conference Call.
Progressive Care Announces Shareholder Conference Call and Business Update on November 14, 2022
MIAMI, FL, Nov. 08, 2022...
VERU (VERU) $6.66, Goes Poof.
Veru Provides Update on FDA Advisory Committee Meeting
Market Cap Plunges from...
Progressive Care Launches Native Remote Patient Monitoring Mobile App .
Progressive Care Launches Native Remote Patient Monitoring Mobile App and Physician Portal to Remotely Manage Chronic and Transitional Care
MedAvail Announces Technology Partnership with Progressive Care, Inc (RXMD).
MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”) a technology-based retail pharmacy company, and Progressive Care Inc. (OTCQB: RXMD) ("Progressive Care”) a personalized healthcare...
Cosmos Health (COSM) and Smart for Life (SMFL) Execute Letter of Intent for Strategic...
LOI Calls for the Provision of SMFL Pan-European Access and COSM North American Access for Products and Services
MIAMI...
Smart for Life (SMFL) Featured by New to the Street
Interviews to Air on National Television Including Bloomberg and Fox Business
MIAMI, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Smart...
Revive Therapeutics (RVVTF) Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
Latest article
IA Initiates Analyst Coverage of Principal Solar (Press Release).
Principal Solar, Inc.Mon, March 20, 2023 at 7:30 AM EDT
Institutional Analyst, Inc....
Selling ARK (ARKK) & Buying AXS Short Innovation (SARK) ETF.
Going Short the Market. No Long Dissertation, No Rush. Market Risk Has Appeared, With Minimal Upside, So Time To Act.
We’re Bearish, but we’re up 257% in Provention Bio (PRVB) Today.
And up 416%, from Adding it to 2022 Watch List!
Great way to wake up after a night of...
